Kryt Chattrabhuti, MD
Nephrology · Annapolis, MDNPI 1346683935
Payments from drug & device makers
Across 53 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$134
- Travere Therapeutics, Inc.$129
- Novartis$117
- AstraZeneca$101
- Fresenius USA Marketing, Inc.$78
- GSK$62
- plus $251 from 6 others
What the payments were for
- Food & beverage$80492%
- Education$688%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 6 | $134 |
| Travere Therapeutics, Inc. | 20 | $129 |
| Novartis | 3 | $117 |
| AstraZeneca(2 entities) | 4 | $101 |
| Fresenius USA Marketing, Inc. | 4 | $78 |
| GSK | 4 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| Calliditas Therapeutics US Inc. | 2 | $51 |
| Vifor Pharma, Inc. | 3 | $47 |
| Boehringer Ingelheim | 2 | $41 |
| Ardelyx, Inc. | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
How this compares
$872 in reported general payments places this provider in the 55th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeltassaPatiromer Calcium Sorbitex | 11 | $20,663 |
| ProsolParenteral Amino Acid 20% No.1 | 64 | $14,075 |
| ClinisolParenteral Amino Acid 15% No.5 | 27 | $4,499 |
| Hydralazine Hcl | 28 | $706 |
| Carvedilol | 18 | $651 |
| Atorvastatin Calcium | 65 | $548 |
| Tamsulosin Hcl | 23 | $476 |
| Furosemide | 42 | $460 |
| Rosuvastatin Calcium | 11 | $393 |
| Famotidine | 16 | $307 |
| Pantoprazole Sodium | 13 | $300 |
| Losartan Potassium | 37 | $251 |
| Amlodipine Besylate | 40 | $231 |
| Colchicine | 12 | $229 |
| Allopurinol | 28 | $189 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Annapolis
- Christopher SperatiBaltimore$1.5M
- Michelle EstrellaBaltimore$1.2M
- Mohamed AttaBaltimore$1.1M
- Chirag ParikhBaltimore$1M
- Mario BelledonnePotomac$715K
- Matthew WeirBaltimore$518K
- Kiran SamindlaFrederick$491K
- Saeed KronfliTakoma Park$463K
- Duvuru GeethaBaltimore$409K
- Preeti ChandraBaltimore$287K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.